Search results for Rosopatamab

Rosopatamab Biosimilar – Anti-FOLH1 mAb – Research Grade, ProteoGenix, PX-TA1712

Description of Rosopatamab Biosimilar - Anti-FOLH1 mAb - Research Grade Introduction to Rosopatamab Biosimilar Rosopatamab Biosimilar, also known as Anti-FOLH1 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Rosopatamab antibody. This biosimilar has been designed to target the FOLH1 protein, which is overexpressed in certain types of cancer. In this article, we will explore the structure, activity, and potential applications of Rosopatamab Biosimilar in the field of cancer research. Structure of Rosopatamab Biosimilar Rosopatamab Biosimilar is a monoclonal antibody that is produced in a laboratory using recombinant DNA technology. It is a humanized antibody, meaning that it contains both human and non-human components. The antibody is composed of two identical heavy chains and two identical light chains, which are linked together by disulfide bonds. The heavy chains are responsible for the binding of the antibody to its target, while the light chains help to stabilize the structure of the antibody. Activity of Rosopatamab Biosimilar The primary function of Rosopatamab Biosimilar is to bind to the FOLH1 protein, which is a cell surface receptor that is highly expressed in certain types of cancer cells. This binding leads to the activation of the body’s immune system, specifically the complement system, which helps to destroy the cancer cells. In addition, the antibody also has the ability to induce antibody-dependent cellular cytotoxicity (ADCC), which involves the recruitment of immune cells to attack and kill the cancer cells. Applications of Rosopatamab Biosimilar Rosopatamab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer, including prostate cancer, ovarian cancer, and bladder cancer. The antibody has also been investigated for its potential as a targeted therapy for patients with advanced or metastatic cancer. One of the major advantages of Rosopatamab Biosimilar is its potential as a biosimilar. As a biosimilar, it has a similar structure and activity to the original Rosopatamab antibody, but at a lower cost. This makes it more accessible for patients who may not be able to afford the original antibody. In addition, the use of biosimilars can also help to reduce the burden on healthcare systems. Targeting FOLH1 in Cancer FOLH1, also known as folate hydrolase 1 or prostate-specific membrane antigen (PSMA), is a transmembrane protein that is highly expressed in several types of cancer, including prostate, ovarian, and bladder cancer. It is involved in the uptake and metabolism of folate, a B vitamin that is essential for cell growth and division. Overexpression of FOLH1 has been linked to increased tumor growth, invasion, and resistance to therapy, making it an attractive therapeutic target. Rosopatamab Biosimilar as a Therapeutic Antibody The development of Rosopatamab Biosimilar as a biosimilar to the original Rosopatamab antibody is a significant advancement in the field of cancer research. By targeting FOLH1, this antibody has the potential to specifically attack cancer cells while sparing healthy cells, reducing the side effects commonly associated with traditional cancer treatments. In addition, the antibody’s ability to activate the immune system and induce ADCC makes it a promising candidate for combination therapy with other cancer treatments. Conclusion In summary, Rosopatamab Biosimilar is a monoclonal antibody that has been developed as a biosimilar to the original Rosopatamab antibody. Its primary function is to bind to the FOLH1 protein, which is overexpressed in certain types of cancer, and activate the immune system to destroy cancer cells. With its potential as a biosimilar and its promising results in preclinical and clinical studies, Rosopatamab Bios

Rosopatamab, Abbexa, abx831683

Rosopatamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting FOLH1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Rosopatamab Antibody, Abbexa, abx376572

Rosopatamab Antibody is a Rabbit Polyclonal antibody for the detection of Rosopatamab.

Rosopatamab ELISA Kit, ProteoGenix, KPTX239

Description of Rosopatamab ELISA Kit The Structure of Rosopatamab ELISA Kit Rosopatamab ELISA Kit is a highly specialized and sensitive diagnostic tool used in the detection and quantification of the antibody known as Rosopatamab. This kit is designed to specifically target and measure the levels of Rosopatamab in various biological samples, making it a valuable tool in both research and clinical settings. The structure of the Rosopatamab ELISA Kit consists of several components, each playing a crucial role in the accurate and precise detection of the antibody. These components include a microplate coated with a specific antigen, a primary and secondary antibody, and a chromogenic substrate. The Role of the Antigen The microplate used in the Rosopatamab ELISA Kit is coated with a specific antigen that is designed to bind specifically to the Rosopatamab antibody. This antigen is carefully selected and optimized to ensure high sensitivity and specificity in the detection of Rosopatamab. The antigen is immobilized on the surface of the microplate, providing a solid support for the antibody-antigen interaction. The Antibodies: Primary and Secondary The primary antibody used in the Rosopatamab ELISA Kit is a monoclonal antibody that is highly specific to Rosopatamab. This antibody is labeled with an enzyme, such as horseradish peroxidase (HRP), which acts as a reporter molecule in the detection process. The primary antibody binds to the antigen on the microplate, forming an antigen-antibody complex. The secondary antibody is a polyclonal antibody that is also specific to Rosopatamab. This antibody is labeled with a different enzyme, such as alkaline phosphatase (AP). The secondary antibody binds to the primary antibody, forming a sandwich complex with the antigen-antibody complex. The Chromogenic Substrate The chromogenic substrate is the final component of the Rosopatamab ELISA Kit. This substrate is added after the antigen-antibody-enzyme complex has formed. The enzyme labels on the primary and secondary antibodies catalyze a reaction with the chromogenic substrate, resulting in a color change. The intensity of the color is directly proportional to the amount of Rosopatamab present in the sample. The Activity of Rosopatamab ELISA Kit The Rosopatamab ELISA Kit is a highly sensitive and specific diagnostic tool that utilizes the principle of enzyme-linked immunosorbent assay (ELISA). This technique allows for the detection and quantification of Rosopatamab in various biological samples, including serum, plasma, and cell culture supernatant. The activity of the Rosopatamab ELISA Kit is based on the specific binding of the Rosopatamab antibody to the antigen on the microplate. This binding is then amplified by the secondary antibody, resulting in a sandwich complex that can be visualized through the color change of the chromogenic substrate. The Application of Rosopatamab ELISA Kit Rosopatamab is a therapeutic target that has been identified as a potential treatment for various autoimmune diseases, such as rheumatoid arthritis and lupus. The Rosopatamab ELISA Kit is a valuable tool in the development and evaluation of this antibody as a potential therapy. In research settings, the Rosopatamab ELISA Kit can be used to measure the levels of Rosopatamab in different biological samples, providing valuable insights into the efficacy and pharmacokinetics of the antibody. In clinical settings, the kit can be used to diagnose and monitor the levels of Rosopatamab in patients receiving treatment. In addition to its application in the development and evaluation of Rosopatamab, the Rosopatamab ELISA Kit can also be used in the detection of Rosopatamab in other contexts, such as in the assessment of immune responses to infections or in the detection of autoantibodies in autoimmune diseases. In

Rosopatamab ELISA Kit, Abbexa, abx395128

Rosopatamab ELISA Kit is a quantitative ELISA kit for detection of Rosopatamab.

Anti-Rosopatamab Polyclonal Antibody, AntibodySystem, PAG01301

Rosopatamab Biosimilar - Research Grade, ichor.bio, ICH5083

Detects human PMSA

Research Grade Rosopatamab (HC669046), abinScience, HC669046

Rosopatamab Vedotin Biosimilar - Research Grade, ichor.bio, ICH5083V